Nika Pharmaceuticals Files Q2 2024 10-Q/A

TL;DR

Nika Pharma dropped its Q2 10-Q/A. Financials updated.

AI Summary

Nika Pharmaceuticals, Inc. filed a 10-Q/A on November 1, 2024, for the period ending June 30, 2024. The filing includes financial data for the second quarter of 2024 and comparative periods. Key financial items such as preferred stock, common stock, additional paid-in capital, retained earnings, and accumulated translation adjustments are detailed as of December 31, 2023, March 31, 2024, and June 30, 2024.

Why It Matters

This filing provides updated financial information for Nika Pharmaceuticals, allowing investors to assess the company's performance and financial health for the second quarter of 2024.

Risk Assessment

Risk Level: low — This is a routine financial filing (10-Q/A) and does not appear to contain any immediately alarming or significant new disclosures.

Key Numbers

• Q2 2024 — Reporting Period (Financials for the second quarter of 2024 are updated.)
• 2023-12-31 — Balance Sheet Date (Key balance sheet figures are provided as of this date.)
• 2024-03-31 — Balance Sheet Date (Key balance sheet figures are provided as of this date.)
• 2024-06-30 — Balance Sheet Date (Key balance sheet figures are provided as of this date.)

Key Players & Entities

• NIKA PHARMACEUTICALS, INC (company) — Filer of the 10-Q/A
• 20240630 (date) — Period of report
• 20241101 (date) — Filing date
• 7023263615 (phone_number) — Business phone number

FAQ

Key Financial Figures

• $0.0001 — The number of shares of Common Stock, $0.0001 par value of the registrant outstanding
• $156 — Company recognized its first revenue of $156 in the second quarter from the sale of
• $1,848,030 — As a result, the revaluation reserve of $1,848,030, recorded in the standalone financial s
• $168,259 — en reported at their historical cost of $168,259. Additionally, any subsequent depreciat

Filing Documents

• form-10qa.htm (10-Q/A) — 367KB
• exhibit31-1.htm (EX-31.1) — 7KB
• exhibit32-1.htm (EX-32.1) — 3KB
• 0001826466-24-000136.txt ( ) — 2297KB
• nkph-20240630_cal.xml (EX-101.CAL) — 31KB
• nkph-20240630_def.xml (EX-101.DEF) — 79KB
• nkph-20240630_lab.xml (EX-101.LAB) — 172KB
• nkph-20240630_pre.xml (EX-101.PRE) — 150KB
• nkph-20240630.xsd (EX-101.SCH) — 20KB
• form-10qa_htm.xml (XML) — 201KB

Financial

Item 1. Financial 3 Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 (Unaudited) 3 Condensed Consolidated Statements of Operations for the three months Ended June 30, 2024 and 2023 (Unaudited) 4 Condensed Consolidated Statements of Stockholders Deficit for the three months Ended June 30, 2024 and 2023 (Unaudited) 5 Condensed Consolidated Statements of Cash Flows for the three months Ended June 30, 2024 and 2023 (Unaudited) 6 Notes to Unaudited Condensed Consolidated Financial Statements 7

Managements Discussion and

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations 13

Quantitative and

Item 3. Quantitative and Qualitative Disclosures About Market Risks. 16

Controls and Procedures

Item 4. Controls and Procedures 16 PART II. 17

Legal Proceedings

Item 1. Legal Proceedings. 17

Risk Factors

Item 1A. Risk Factors . 17

Unregistered Sales of

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 17

Defaults Upon Senior

Item 3. Defaults Upon Senior Securities. 17

Mine Safety Disclosures

Item 4. Mine Safety Disclosures. 17

Other Information

Item 5. Other Information. 17

Exhibits

Item 6. Exhibits. 17 EXHIBIT INDEX 17

Consolidated Financial Statements

Item 1. Consolidated Financial Statements NIKA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2024 December 31, 2023 ASSETS (Unaudited) (Audited) Current Assets: Cash $ 7,486 $ 19,596 Inventory 14,104 Accounts receivable 196,394 Other receivables 4,080 Total current assets 222,063 19,596 Property, plant, and equipment: Property $ 168,259 Total Property, plant, and equipment: $ 168,259 $ Total assets: $ 390,323 $ 19,596 LIABILITIES AND STOCKHOLDERS DEFICIT Current Liabilities: Accounts payable and other liabilities $ 4,637 $ Due to related parties $ 632,297 $ 101,745 Total Current Liabilities $ 636,934 $ 101,745 Total Liabilities $ 636,934 $ 101,745 Commitments and contingencies Stockholders' Deficit: Preferred Stock; par value $ 0.0001 ; 15,000,000 shares authorized; 15,000,000 and 10,000,000 shares issued and outstanding, respectively 1,500 1,000 Common Stock; par value $ 0.0001 ; 2,700,000,000 shares authorized; 1,018,519,500 and 876,090,000 shares issued and outstanding, respectively 101,852 87,609 Additional paid-in capital 8,606,040 3,229,489 Accumulated other comprehensive income Accumulated deficit ( 8,956,004 ) ( 3,400,247 ) Total Stockholders' Deficit ( 246,611 ) ( 82,149 ) Total Liabilities and Stockholders' Deficit $ 390,323 $ 19,596 The accompanying notes are an integral part of these unaudited consolidated financial statements. 3 NIKA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) For the Three Months Ended For the Six Months Ended June 30, June 30, 2024 2023 2024 2023 Revenue $ 156 $ $ 156 $ Operating Expenses: General and administrative $ 39,999 $ 21,001 $ 61,724 $ 21,871 Professional fees 14,957 6,805 52,457 25,505 Total operating expenses 54,956 27,806 114,181 47,376 Loss from ope

financial statements reflect all adjustments, consisting of only normal

financial statements reflect all adjustments, consisting of only normal recurring items, which, in the opinion of management, are necessary for a fair necessarily indicative of the results to be expected for the full year ending December 31, 2024. These audited consolidated financial statements should be read in conjunction with the financial statements and related notes included in the Companys Annual Report on Form 10-K for the year ended December 31, 2023. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial reporting period. Actual results may differ from those estimates. Concentrations of Credit Risk We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash. Reclassifications Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the financial Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. As of June 30, 2024 and December 31, 2023, the Company had no cash equivalents. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Centennial Ventures, Inc, Nika Phar

financial statements of Nika Pharmaceuticals, Inc. are prepared on a historical

financial statements of Nika Pharmaceuticals, Inc. are prepared on a historical cost basis for property, plant, and equipment. Certain subsidiaries, which report under International Financial Reporting Standards (IFRS), apply the revaluation model to measure their property, plant, and equipment at fair value, with the resulting revaluation surplus recognized in equity as a revaluation reserve. For the purposes of consolidation into the Group's US GAAP

financial statements, any revaluation reserves recognized under IFRS are

financial statements, any revaluation reserves recognized under IFRS are eliminated, and the affected assets are adjusted back to their historical cost basis in accordance with US GAAP. As a result, the revaluation reserve of $1,848,030, recorded in the standalone financial statements of the subsidiary, has been removed in the consolidated financial statements, and the related assets have been reported at their historical cost of $168,259. Additionally, any subsequent depreciation, amortization, or gains/losses on disposal of these assets are calculated based on the adjusted historical cost in compliance with US GAAP. 10 Property and equipment stated at cost, less accumulated depreciation consisted of the following: June 30, 2024 Buildings 168,259 Total $ 168,259 NOTE 6 COMMON STOCK During the six months ended June 30, 2024, pursuant to the terms of the Merger with Nika BioTechnology, Inc (Note 1), the Company issued 142,429,500 shares of common stock of the 204,205,027 shares to be issued. NOTE 7 PREFERRED STOCK On April 8, 2022, the Company filed a certificate of designation establishing the rights and preference of preferred stock with the Secretary of State o

View Full Filing

View this 10-Q/A filing on SEC EDGAR